StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > EBITDA for the quarter was $193,000. A very positive number.

<< Previous

Bullboard Posts

Next >>

Comment by Jonnyboy85on May 19, 2021 7:58pm

117 Views

Post# 33235267

RE:RE:EBITDA for the quarter was $193,000. A very positive number.

Found this on marketwatch, I knew it was high but never crunched the numbers

2020 SALES GROWTH2,925.78%

LithLover wrote: We should be way over a market cap of $34 million.

$7 million in cash and equivalents, the lab, the new LOI, revenues from Covid, revenues from Aristiotle and soon to receive clinic and protocol revenues from Care Oncology. Possitive EBITDA and increased marketing and social media.

This will be moving up very soon.

LithLover wrote: Cash, beginning of period $6,597,187

Cash, end of period $6,443,401

Adjusted EBITDA for the quarter was $193,000.

Revenues coming in with Covid. Covid revenues expected to remain the same for the next couple quarters and Aristotle revenues are starting. In addition with the aquistion of Care Oncology group we will see revenues from that side of their business too.

And still with $6.5 million in the bank.

It's no wonder the short and distort team is trying so hard. They need shares badly and can't afford a squeeze here. Yet they aren't getting the volume they need. Bad enough they have to attack a cancer detection stock but when its not shaking shares loose that makes them grumpy. LOL